Persistent dynamic phase of aurothioglucose obesity

1963 ◽  
Vol 205 (5) ◽  
pp. 919-921 ◽  
Author(s):  
Gerald Friedman ◽  
Jerome D. Waye ◽  
Henry D. Janowitz
Keyword(s):  
Food Intake ◽  
Obese Mice ◽  
Control Groups ◽  
Gradual Decline ◽  
Total Period ◽  
Dynamic Phase ◽  
Time Period ◽  
Daily Food ◽  
And Control

Continuous long-term observations on food intake, body weight, and the development of obesity were made on the survivors of an ld50 dose of aurothioglucose (ATG). ATG-obese mice consumed significantly greater amounts of food compared to ATG-nonobese and control animals from the 2nd to the 13th months of observation. The daily food consumption of obese animals remained relatively constant from the inception of hyperphagia to senescence. Food intake in the two control groups remained constant throughout 18 months of observation. Throughout the latter time period the obese animals had significantly greater weights than their ATG-nonobese and control littermates. No significant differences in weights were noted between ATG-nonobese mice and controls during the total period of observation. Obese mice progressively gained weight until the 12th month, after which a gradual decline was observed. At no time was a weight plateau evident. It is concluded that the long-term progressive weight gain in ATG-obese mice is consistent with a persistent dynamic phase of obesity until senescence.

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.

1991 ◽  
Vol 9 (5) ◽  
pp. 736-740 ◽  
Author(s):  
L E Spitler
Keyword(s):  
Malignant Melanoma ◽  
Adjuvant Therapy ◽  
Randomized Trial ◽  
Control Groups ◽  
Disease Free Interval ◽  
Significant Difference ◽  
Long Term Follow Up ◽  
And Control

We conducted a long-term follow-up (median, 10.5 years) of patients included in a randomized trial of levamisole versus placebo as surgical adjuvant therapy in 203 patients with malignant melanoma. Of the patients randomized, 104 received levamisole, and 99 received placebo. The results show that there is no difference between the treatment and control groups with regard to any of the three end points analyzed. These included disease-free interval, time to appearance of visceral metastasis, and survival. Moreover, there was no significant difference between the treatment and control groups after adjusting for age, sex, or stage of disease.

scholarly journals EEG Based Classification of Long-Term Stress Using Psychological Labeling

Sensors ◽  
2020 ◽  
Vol 20 (7) ◽  
pp. 1886 ◽  
Author(s):  
Sanay Muhammad Umar Saeed ◽  
Syed Muhammad Anwar ◽  
Humaira Khalid ◽  
Muhammad Majid ◽  
Ulas Bagci
Keyword(s):  
Objective Measure ◽  
Machine Learning Algorithms ◽  
Support Vector ◽  
Eeg Signal ◽  
Expert Evaluation ◽  
Clinical Practices ◽  
Control Groups ◽  
Alpha Asymmetry ◽  
And Control

Stress research is a rapidly emerging area in the field of electroencephalography (EEG) signal processing. The use of EEG as an objective measure for cost effective and personalized stress management becomes important in situations like the nonavailability of mental health facilities. In this study, long-term stress was classified with machine learning algorithms using resting state EEG signal recordings. The labeling for the stress and control groups was performed using two currently accepted clinical practices: (i) the perceived stress scale score and (ii) expert evaluation. The frequency domain features were extracted from five-channel EEG recordings in addition to the frontal and temporal alpha and beta asymmetries. The alpha asymmetry was computed from four channels and used as a feature. Feature selection was also performed to identify statistically significant features for both stress and control groups (via t-test). We found that support vector machine was best suited to classify long-term human stress when used with alpha asymmetry as a feature. It was observed that the expert evaluation-based labeling method had improved the classification accuracy by up to 85.20%. Based on these results, it is concluded that alpha asymmetry may be used as a potential bio-marker for stress classification, when labels are assigned using expert evaluation.

A comparison of the effects of body condition and short-term food restriction on the feeding behaviour of sheep

1996 ◽  
Vol 1996 ◽  
pp. 174-174
Author(s):  
A.M. Sibbald
Keyword(s):  
Food Intake ◽  
Body Condition ◽  
Feeding Behaviour ◽  
Food Restriction ◽  
Term Effect ◽  
Short Term ◽  
Daily Food ◽  
Long Term Effect ◽  
Single Meal

Voluntary food intake is generally inversely related to body condition or fatness in mature sheep (Foot, 1972). Since the intake of pelleted diets by housed sheep consists of a number of discrete feeding bouts or 'meals' (e.g. Bermudez et al., 1989), the relatively long-term effect of body condition on intake will be achieved through changes in feeding behaviour at the level of a single meal. The aim of this experiment was to compare the effects of body condition and short-term food restriction on meal patterns in sheep, to investigate the mechanism by which body condition influences daily food intake.

scholarly journals Comparative Evaluation of Infected and NoninfectedAmblyomma tristeTicks withRickettsia parkeri, the Agent of an Emerging Rickettsiosis in the New World

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
F. A. Nieri-Bastos ◽  
M. P. J. Szabó ◽  
R. C. Pacheco ◽  
J. F. Soares ◽  
H. S. Soares ◽  
...  
Keyword(s):  
Infected Group ◽  
Control Group ◽  
Control Groups ◽  
Rickettsia Parkeri ◽  
Amblyomma Triste ◽  
Vertebrate Hosts ◽  
Domestic Rabbits ◽  
And Control ◽  
Term Maintenance

The distribution ofRickettsia parkeriin South America has been associated withAmblyomma tristeticks. The present study evaluated under laboratory conditions two colonies ofA. triste: one started from engorged females that were naturally infected byR. parkeri(designated as infected group); the other started from noninfected females (designated as control group). Both colonies were reared in parallel for five consecutive generations. Tick-naïve domestic rabbits were used for feeding of each tick stage and generation.R. parkeriwas preserved by transstadial maintenance and transovarial transmission inA. tristeticks for five consecutive generations, because all tested larvae, nymphs, and adults from the infected group were shown by PCR to contain rickettsial DNA. All rabbits infested by larvae, nymphs, and adults from the infected group seroconverted, indicating that these tick stages were all vector competent forR. parkeri. Expressive differences in mortality rates were observed between engorged nymphs from the infected and control groups, as indicated by 65.9% and 92.4% molting success, respectively. Our results indicate thatA. tristecan act as a natural reservoir forR. parkeri. However, due to deleterious effect caused byR. parkerion engorged nymphs, amplifier vertebrate hosts might be necessary for natural long-term maintenance ofR. parkeriinA. triste.

Immunotherapy with Autologous Anti-CD19 Chimeric Antigen Receptor T Cells Followed By Allogeneic Hematopoietic Stem Cell Transplantation Has Remarkably Improved Leukemia-Free Survival in Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 829-829
Author(s):  
Yan-Li Zhao ◽  
Tong Wu ◽  
De-Yan Liu ◽  
Jian-Ping Zhang ◽  
Zhi-Jie Wei ◽  
...  
Keyword(s):  
Stem Cell ◽  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Control Group ◽  
Control Groups ◽  
Hematopoietic Stem ◽  
Free Survival ◽  
Allogeneic Hsct ◽  
Time Period ◽  
And Control

Abstract Introduction: The prognosis of refractory/relapsed acute lymphoblastic leukemia (ALL) is poor with chemotherapy or even allogeneic hematopoietic stem cell transplantation (HSCT). Although our immunotherapy with autologous anti-CD19 chimeric antigen receptor T cells (CART) has resulted in 88.6% complete remission (CR) in refractory/relapsed B-cell ALL (B-ALL), many patients relapsed at around 2 months after CART therapy (unpublished data). Our current strategy is to perform HSCT for refractory/relapsed B-ALL in CR by CART therapy to attain continuous leukemia-free survival (LFS). However, majority of the patients with CART therapy developed cytokine release syndrome which may increase transplant-related mortality (TRM). Moreover, all patients with CART therapy have very tough diseases which could result in higher relapse rate after transplant. Objective: In current study, the safety and efficacy of HSCT for refractory/relapsed B-ALL after CART therapy were investigated. The patients with B-ALL who received HSCT during the same time period without CART therapy were as control. Patients and Methods: Between July 2015 and May 2016, consecutive 22 patients with refractory/relapsed CD19+ B-ALL in CR by CART therapy followed by allogeneic HSCT in our hospital were analyzed as CART group; and consecutive 89 patients with B-ALL in CR who received allogeneic HSCT in our hospital during the same time period but without previous CART therapy were as control group. Clinical characteristics between two groups was comparable except more CR1 (22.7% vs. 57.3%) in control group and more CD3+ cells infused (1.93x108/kg vs. 1.46 x108/kg, p=0.026) in CART group. The median age was 8 (2-44) years, 15 (2-52) years in CART and control groups (p=0.147). The median disease course was 19.1 (3.9-53.7) months, 10.6 (3.7-123.0) months in CART and control groups (p=0.385). The median time from CART therapy to HSCT was 86 (31-172) days. Disease status was 22.7% cases in CR1, 54.5% in CR2, 18.2% in CR3 and 4.5% in CR4 in CART group; and 57.3% cases in CR1, 36.0% in CR2 and 6.7% in CR3 in control group (p=0.08). Minimal residual disease pre-conditioning by flow cytometry was positive in 22.7%, 31.5% patients in CART and control groups (p=0.422). Donor source was identical sibling (IS) in 13.6%, unrelated (UR) in 31.8% and haploidentical (HI) in 54.5% in CART group; and IS in 14.6%, UR in 16.9% and HI in 68.5% in control group (p=0.313). Myeloablative conditioning regimens were administered with either total body irradiation (TBI) plus cyclophosphamide (Cy)/ fludarabine (Flu)-based in 90.9% cases or busulfan (Bu) plus Cy/ Flu-based in 9.1% cases in CART group; and TBICY/Flu-based in 85.4% cases or BuCy/Flu-based in 14.6% cases in control group (p=0.498). Antithymocyte globulin was used in UR and HI transplants. Cyclosporine, short-term methotrexate, and mycophenolate mofetil were employed for GVHD prophylaxis. Results: The median time to neutrophil engraftment was similar between two groups (14 days vs. 13 days, p=0.196), but platelet engraftment was slower in CART group (14 days vs. 12 days, p=0.031). Cumulative incidence of grade II-IV acute GVHD (aGVHD) was higher in CART group (57.6% vs. 33.1%, p=0.009), which may related to higher CD3+ cells infused in CART cohort; but the incidences of grade III-IV aGVHD were no statistical significance (25.1% vs. 15.7%, p=0.564) in two groups. No remarkable differences were seen in CMV reactivation (45% vs. 51.7%, p=0.601) and transplant-associated thrombotic microangiopathy (13.6% vs. 9.0%, p=0.514) in two groups. No significant difference was found in TRM between CART and control groups (7.1% vs. 15.2%, p=0.808). Relapse rates were similar in two groups (5.0% vs. 6.9%, p=0.888). With a median follow-up 9 (2-12) months, LFS was comparable in CART and control groups (84.8% vs. 80.9%, p=0.937). Conclusions: Our preliminary results have shown that the strategy with CART therapy followed by allogeneic HSCT in refractory/relapsed B-ALL is very safe and effective with similar outcomes in TRM, relapse rate and LFS compared with control group. CART therapy has resulted in very good CR in refractory/relapsed B-ALL and allowed the patients to achieve continuous LFS by subsequent allogeneic HSCT, which is revolutionary modality for those patients who have otherwise incurable diseases. Disclosures No relevant conflicts of interest to declare.

scholarly journals Long-Term Effects of AposTherapy in Patients with Osteoarthritis of the Knee: A Two-Year Followup

Arthritis ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Yaron Bar-Ziv ◽  
Eytan M. Debbi ◽  
Yuval Ran ◽  
Shaike Benedict ◽  
Nahum Halperin ◽  
...  
Keyword(s):  
Active Group ◽  
Long Term Effects ◽  
Control Groups ◽  
Knee Oa ◽  
Sf 36 ◽  
Physical Scale ◽  
And Function ◽  
And Control ◽  
Knee Society Function Score

Several biomechanics treatments for knee osteoarthritis (OA) have emerged with the goal of reducing pain and improving function. Through this, researchers have hoped to achieve a transition from the pathological gait patterns to coordinated motor responses. The purpose of the study was to determine the long-term effects of a therapy using a biomechanical device in patients with knee OA. Patients with knee OA were enrolled to active and control groups. The biomechanical device used in therapy (AposTherapy) was individually calibrated to each patient in the active group. Patients in the control group received standard treatment. Outcomes were the Western Ontario and McMaster Osteoarthritis Index (WOMAC), Aggregated Locomotor Function (ALF), Short Form 36 (SF-36), and Knee Society Score assessments. The active and control groups were similar at the baseline (group difference in all scores ). The active group showed a larger improvement over time between groups in all three WOMAC categories (, 21.7, and 18.1 for pain, stiffness, and function; all ), SF-36 Physical Scale (; ), Knee Society Knee Score (; ), and Knee Society Function Score (; ). At the two-year endpoint, the active group showed significantly better results (all ). The groups showed a difference of 4.9, 5.6, and 4.7 for the WOMAC pain, stiffness, and function scores, respectively, 10.8 s in ALF score, 30.5 in SF-36 Physical Scale, 16.9 in SF-36 Mental Scale, 17.8 in Knee Society Knee Score, and 25.2 in Knee Society Function Score. The biomechanical therapy examined was shown to significantly reduce pain and improve function and quality of life of patients with knee OA over the long term.

scholarly journals Effectiveness of Smartphone App–Based Interactive Management on Glycemic Control in Chinese Patients With Poorly Controlled Diabetes: Randomized Controlled Trial

10.2196/15401 ◽  
2019 ◽  
Vol 21 (12) ◽  
pp. e15401 ◽  
Author(s):  
Lei Zhang ◽  
Xingxing He ◽  
Yun Shen ◽  
Haoyong Yu ◽  
Jiemin Pan ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Controlled Trial ◽  
Chinese Patients ◽  
Self Management ◽  
Control Groups ◽  
Randomized Controlled ◽  
Management Group ◽  
Interactive Management ◽  
And Control

Background In recent years, the rapid development of mobile medical technology has provided multiple ways for the long-term management of chronic diseases, especially diabetes. As a new type of management model, smartphone apps are global, convenient, cheap, and interactive. Although apps were proved to be more effective at glycemic control, compared with traditional computer- and Web-based telemedicine technologies, how to gain a further and sustained improvement is still being explored. Objective The objective of this study was to investigate the effectiveness of an app-based interactive management model by a professional health care team on glycemic control in Chinese patients with poorly controlled diabetes. Methods This study was a 6-month long, single-center, prospective randomized controlled trial. A total of 276 type 1 or type 2 diabetes patients were enrolled and randomized to the control group (group A), app self-management group (group B), and app interactive management group (group C) in a 1:1:1 ratio. The primary outcome was the change in glycated hemoglobin (HbA1c) level. Missing data were handled by multiple imputation. Results At months 3 and 6, all 3 groups showed significant decreases in HbA1c levels (all P<.05). Patients in the app interactive management group had a significantly lower HbA1clevel than those in the app self-management group at 6 months (P=.04). The average HbA1c reduction in the app interactive management group was larger than that in the app self-management and control groups at both months 3 and 6 (all P<.05). However, no differences in HbA1c reduction were observed between the app self-management and control groups at both months 3 and 6 (both P>.05). Multivariate line regression analyses also showed that the app interactive management group was associated with the larger reduction of HbA1c compared with groups A and B at both months 3 and 6 (all P>.05). In addition, the app interactive management group had better control of triglyceride and high-density lipoprotein cholesterol levels at both months 3 and 6 compared with baseline (both P<.05). Conclusions In Chinese patients with poorly controlled diabetes, it was difficult to achieve long-term effective glucose improvement by using app self-management alone, but combining it with interactive management can help achieve rapid and sustained glycemic control. Trial Registration ClinicalTrials.gov NCT02589730; https://clinicaltrials.gov/ct2/show/NCT02589730.

scholarly journals Effectiveness of Smartphone App–Based Interactive Management on Glycemic Control in Chinese Patients With Poorly Controlled Diabetes: Randomized Controlled Trial (Preprint)

2019 ◽  
Author(s):  
Lei Zhang ◽  
Xingxing He ◽  
Yun Shen ◽  
Haoyong Yu ◽  
Jiemin Pan ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Controlled Trial ◽  
Chinese Patients ◽  
Self Management ◽  
Control Groups ◽  
Randomized Controlled ◽  
Management Group ◽  
Interactive Management ◽  
And Control

BACKGROUND In recent years, the rapid development of mobile medical technology has provided multiple ways for the long-term management of chronic diseases, especially diabetes. As a new type of management model, smartphone apps are global, convenient, cheap, and interactive. Although apps were proved to be more effective at glycemic control, compared with traditional computer- and Web-based telemedicine technologies, how to gain a further and sustained improvement is still being explored. OBJECTIVE The objective of this study was to investigate the effectiveness of an app-based interactive management model by a professional health care team on glycemic control in Chinese patients with poorly controlled diabetes. METHODS This study was a 6-month long, single-center, prospective randomized controlled trial. A total of 276 type 1 or type 2 diabetes patients were enrolled and randomized to the control group (group A), app self-management group (group B), and app interactive management group (group C) in a 1:1:1 ratio. The primary outcome was the change in glycated hemoglobin (HbA<sub>1c</sub>) level. Missing data were handled by multiple imputation. RESULTS At months 3 and 6, all 3 groups showed significant decreases in HbA<sub>1c</sub> levels (all <italic>P</italic>&lt;.05). Patients in the app interactive management group had a significantly lower HbA<sub>1c</sub>level than those in the app self-management group at 6 months (<italic>P</italic>=.04). The average HbA<sub>1c</sub> reduction in the app interactive management group was larger than that in the app self-management and control groups at both months 3 and 6 (all <italic>P</italic>&lt;.05). However, no differences in HbA<sub>1c</sub> reduction were observed between the app self-management and control groups at both months 3 and 6 (both <italic>P</italic>&gt;.05). Multivariate line regression analyses also showed that the app interactive management group was associated with the larger reduction of HbA<sub>1c</sub> compared with groups A and B at both months 3 and 6 (all <italic>P</italic>&gt;.05). In addition, the app interactive management group had better control of triglyceride and high-density lipoprotein cholesterol levels at both months 3 and 6 compared with baseline (both <italic>P</italic>&lt;.05). CONCLUSIONS In Chinese patients with poorly controlled diabetes, it was difficult to achieve long-term effective glucose improvement by using app self-management alone, but combining it with interactive management can help achieve rapid and sustained glycemic control. CLINICALTRIAL ClinicalTrials.gov NCT02589730; https://clinicaltrials.gov/ct2/show/NCT02589730.

scholarly journals Concomitant Use of Diosmin/Hesperidin and Oral Rivaroxaban Increases Deep Vein Recanalization and Reduces the Incidence of Post-Thrombotic Syndrome in Patients with Proximal Deep Vein Thrombosis

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 986-986
Author(s):  
Kirill Lobastov ◽  
Iliya Schastlivtsev ◽  
Victor Barinov
Keyword(s):  
Deep Vein Thrombosis ◽  
Clinical Severity ◽  
Proximal Deep Vein Thrombosis ◽  
Control Groups ◽  
Vein Thrombosis ◽  
Post Thrombotic Syndrome ◽  
And Control ◽  
Deep Vein ◽  
The Impact

Abstract Aim: To assess the impact of long-term Diosmin/Hesperidin use in the treatment of proximal deep vein thrombosis (DVT). Methods: This study was a pilot randomized open-label study with blinded outcome assessor - enrolled patients with their first episodes of popliteal-femoral DVT confirmed by duplex ultrasound (DUS). All participants were randomized into two groups: 1.) control that received a standard treatment with oral Rivaroxaban, and 2.) experimental that required additional treatment with Diosmin/Hesperidin 450/50 mg twice a day. Both drugs were used for six months. Patients were followed-up for the whole treatment period with series DUS every two months in order to evaluate the degree of recanalization by popliteal (PV), superficial femoral (SFV), and common femoral (CFV) veins' compressibility. Thrombi extension was assessed by modified Marder score. At the end of the follow-up period, patients were assessed with Villalta and venous clinical severity scores. Post-thrombotic syndrome (PTS) was diagnosed in those who had ≥5 Villalta score. Results: Sixty patients were randomized to the control and experimental groups (n=30 in each group). There were 40 men and 20 women with mean age of 56.3±13.4. Clinically unprovoked DVT was recognized in 65% of cases and left side localization in 45%. The median of Marder baseline scores were 15.0±4.8 and 11.1±4.3 in the experimental and control groups, respectively (p=0.002). After six months of treatment, the Marder score decreased to 0.8±1.6 and 2.8±3.5 in the main control groups, respectively (p=0.006). The generalized linear model repeated measures found a greater reduction in the Marder score (р <0.0001) and increased speed of recanalization on SFV (р <0.0001) with a non-significant tendency in the CFV (p=0.130) and PV (p=0.204) in the experimental group compared to the control one. Full recanalization of the PV at six months was observed in 24 patients (80%), who had received Diosmin/Hesperidin, and only in 17 persons (57%) of the control group (p=0.047). The median of Villalta score in the group treated with Diosmin/Hesperidin was significantly lower compared to the control one (2.9±2.7 versus 5.8±3.0 [p <0.0001]). The same difference was found for VCSS score (2.3±1.9 versus 4.9±1.9 [p <0001]). According to the Villalta score, PTS was recognized in six patients (20%) and 17 patients (57%) in the experimental and control groups, respectively (p=0.004). Conclusion: Long-term treatment with Diosmin/Hesperidin can increase the speed of deep vein recanalization and reduce the incidence of PTS diagnosed at six months in patients with proximal DVT treated with oral rivaroxaban. Disclosures Lobastov: Bayer: Honoraria, Speakers Bureau; Servier: Honoraria, Speakers Bureau. Schastlivtsev:Bayer: Honoraria, Speakers Bureau; Servier: Honoraria, Speakers Bureau. Barinov:Bayer: Honoraria, Speakers Bureau; Servier: Honoraria, Speakers Bureau.

Sign in / Sign up

Export Citation Format

Share Document